

~~BASE~~

Serial No. 09/782,306

WENZEL et al.


PT 51202

APPENDIX I.

CLAIM AMENDMENTS:

Cancel Claims 2 and 13, and amend Claim 1, as indicated in the following listing of the claims:

1. (currently amended) A neutraceutical composition for inhibiting COX-2 biosynthesis or COX-2- and NF- $\kappa$ B-biosynthesis comprising a therapeutically effective amount of the compound of formula I



wherein

R<sup>1</sup> and R<sup>4</sup> represent either hydrogen or together a bond,  
R<sup>5</sup>, R<sup>6</sup>, R<sup>7</sup>, R<sup>8</sup> represent independently of each other hydrogen, hydroxy or methoxy, in addition R<sup>1</sup> represents a sugar substituent,  
R<sup>2</sup> represents and R<sup>3</sup> represent hydrogen, hydroxy, methoxy, or



wherein R<sup>2'</sup>, R<sup>3'</sup>, R<sup>4'</sup>, R<sup>5'</sup>, and R<sup>6'</sup> are independently of each other hydrogen, hydroxy or methoxy, wherein R<sup>1</sup> is a flavone, 5-OH flavone, 7-OH flavone and 7,8 (OH)<sub>2</sub> flavone, with the proviso that R<sup>2</sup> or R<sup>3</sup> is represented by the phenyl ring optionally substituted

R<sup>3</sup> represents hydrogen.

and a pharmaceutically acceptable carrier.

2. - 13. (canceled)

Enter This Amendment  
ES0